Importantly, this study provides compelling evidence of a clinically relevant pharmacological approach to target the duodenal Hif2α‐Fpn axis as a novel strategy to improve various forms of refractory hepcidin‐activated anemias. This evidence concerns the gene SLC40A1 and anemia (phenotype).